Target type: biologicalprocess
The process of introducing a phosphate group into a carbohydrate, any organic compound based on the general formula Cx(H2O)y. [ISBN:0198506732]
Carbohydrate phosphorylation is a fundamental biochemical process that plays a crucial role in various cellular functions, including energy metabolism, signal transduction, and biosynthesis. It involves the addition of a phosphate group (PO43-) to a carbohydrate molecule, typically a sugar or a sugar derivative. This process is catalyzed by enzymes known as kinases, which specifically recognize and phosphorylate hydroxyl groups on the carbohydrate molecule. The phosphorylation of carbohydrates alters their chemical properties and can lead to several important consequences:
1. **Energy Storage and Utilization:** In glycolysis, the breakdown of glucose for energy production, phosphorylation of glucose traps it within the cell and facilitates its subsequent metabolism. The phosphate group, when removed, releases energy that can be used to drive other cellular processes.
2. **Signal Transduction:** Phosphorylation of carbohydrates can act as a molecular switch, altering their ability to interact with other molecules and triggering downstream signaling events. For instance, the phosphorylation of glucose by hexokinase can activate downstream signaling pathways involved in glucose uptake and metabolism.
3. **Regulation of Enzyme Activity:** Phosphorylation can modulate the activity of enzymes involved in carbohydrate metabolism. For example, phosphorylation of glycogen phosphorylase activates the enzyme, leading to the breakdown of glycogen for glucose release.
4. **Carbohydrate Transport:** Phosphorylation can facilitate the transport of carbohydrates across cell membranes. For example, glucose phosphorylation by hexokinase allows glucose to be trapped inside cells, promoting its further metabolism.
5. **Biosynthesis:** Phosphorylation is essential for the synthesis of complex carbohydrates like glycogen and starch. Phosphorylated sugars act as precursors and intermediates in these biosynthetic pathways.
The process of carbohydrate phosphorylation is highly regulated and involves a complex interplay of enzymes, substrates, and cellular conditions. This precise regulation ensures that phosphorylation occurs at the appropriate time and location, allowing for the efficient and coordinated control of cellular processes.
'"
Protein | Definition | Taxonomy |
---|---|---|
Hexokinase-4 | A hexokinase-4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P35557] | Homo sapiens (human) |
Hexokinase-2 | A hexokinase-2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P52789] | Homo sapiens (human) |
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 | A 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16875] | Homo sapiens (human) |
Galactokinase | A galactokinase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P51570] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
benserazide | benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone. Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone. | carbohydrazide; catechols; primary alcohol; primary amino compound | antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor |
staurosporine | indolocarbazole alkaloid; organic heterooctacyclic compound | apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector | |
2-(4-hydroxyphenyl)-5,6,7,8-tetrahydroxy-4H-1-benzopyran-4-one | 2-(4-hydroxyphenyl)-5,6,7,8-tetrahydroxy-4H-1-benzopyran-4-one : A pentahydroxyflavone that is flavone substituted by hydroxy groups at positions 5, 6, 7, 8, and 4' respectively. | pentahydroxyflavone | |
zm 241385 | ZM 241385: a high affinity radioligand selective for the A2a adenosine receptor | diamino-1,3,5-triazine | |
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one | quinazolines | ||
andrographolide | carbobicyclic compound; gamma-lactone; labdane diterpenoid; primary alcohol; secondary alcohol | anti-HIV agent; anti-inflammatory drug; antineoplastic agent; metabolite | |
4',7,8-trihydroxyisoflavone | 4',7,8-trihydroxyisoflavone: from Streptomyces sp OH-1049; structure given in first source | isoflavones | |
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one | 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one: 6-phosphofructo-2-kinase-fructose-2,6-bisphosphatase isozymes inhibitor; structure in first source | enone; pyridines | angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.1.105 (6-phosphofructo-2-kinase) inhibitor |
ro-28-1675 | acetamides | ||
piragliatin | piragliatin: glucokinase activator | ||
pf-04991532 | |||
pf-04937319 | N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide: a glucokinase activator; structure in first source | ||
agi-5198 | AGI-5198: inhibits isocitrate dehydrogenase 1; structure in first source |